

Multiple Sclerosis (MS) Clinically Isolated Syndrome (CIS)

## A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

**Trial Status**

Active, not recruiting

**Trial Runs In**

5 Countries

**Trial Identifier**

NCT04998812 2021-000062-14  
MN42988

The source of the below information is the publicly available website *ClinicalTrials.gov*. It has been summarised and edited into simpler language.

### ***Trial Summary:***

This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

**Hoffmann-La Roche**

Sponsor

**Phase 4**

Phase

NCT04998812 2021-000062-14 MN42988

Trial Identifiers

### ***Eligibility Criteria:***

**Gender**

Female

**Age**

>=18 Years & <= 40 Years

**Healthy Volunteers**

No